

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Bakhit et al. ) Examiner: Applied For  
Customer No.: 51957 )  
Serial Number: 10/521,367 ) Art Unit: Applied For  
Filed: January 12, 2005 ) Confirmation No.: Applied For  
For: COMPOSITIONS AND METHODS )  
COMPRISING PROSTAGLANDIN- )  
RELATED COMPOSITIONS AND )  
TREFOIL FACTOR FAMILY PEPTIDES )  
FOR THE TREATMENT OF )  
GLAUCOMA WITH REDUCED )  
HYPEREMIA )  
\_\_\_\_\_  
Irvine, California

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicants provide with regard to the patent application entitled **COMPOSITIONS AND METHODS COMPRISING PROSTAGLANDIN-RELATED COMPOSITIONS AND TREFOIL FACTOR FAMILY PEPTIDES FOR THE TREATMENT OF GLAUCOMA WITH REDUCED HYPEREMIA** filed herewith one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).


While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material

documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: 6-16, 2005

  
\_\_\_\_\_  
BRENT A. JOHNSON  
Registration Number 51,851

Please direct all inquiries and correspondence to:


Brent A. Johnson  
Allergan, Inc.  
2525 Dupont Drive, T2-7H  
Irvine, California 92623-9534  
Tel: 714 246 4348  
Fax: 714 246 4249

**CERTIFICATE OF FIRST CLASS MAIL UNDER 37 C.F.R. § 1.10**

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date 6-16 2005, in an envelope as "First Class Mail Post Office to Addressee" Mailing US addressed to: Attn: Information Disclosure Statement, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date 6-16 2005

Bonnie Ferguson  
Name of person mailing paper

  
Signature of person mailing paper

**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17629 (AP)	SERIAL NO.: 10/521,367
APPLICANT: Bakhi et al <i>JUN 20 2005</i> U.S. PATENT & TRADEMARK OFFICE	TITLE: COMPOSITIONS AND METHODS COMPRISING MEMANTINE AND POLYANIONIC POLYMERS
FILING DATE: January 12, 2005	GROUP: Applied for

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
AA	5,688,819	11/18/1997	Woodward et al			
AB	6,525,018	2/25/2003	Podolsky			

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
AC	WO 02102403	Dec. 27, 2002	PCT			

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)**

AD	Francis A. Carey, Organic Chemistry, New York: McGraw-Hill Book Company, 1987, 779
AE	Bezuglov et al, "Synthesis and Biological Evaluation of Novel Amides of Polyunsaturated Fatty Acids with Dopamine", Biorganic & Medicinal Chemistry Letters 11 (2001), 447-449
AF	Hauser et al, "hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus", Proc Natl Acad Sci USA, 1993, Vol. 90, 6961-6965
AG	Babyatsky et al, "Oral Trefoil Peptides Protect Against Ethanol- and Indomethacin-Induced Gastric Injury in Rats", Gastroenterology, 1996, Vol. 110, 489-497
AH	Goke et al, "Trefoil Peptides Promote Restitution of Wounded Corneal Epithelial Cells", Experimental Cell Research, 2001, Vol. 264, 337-344
AI	Playford, "Trefoil peptides: what are they and what do they do?? Journal of the Royal College of Physicians of London, Vol. 31, 37-40
AJ	Langer et al, "Secretory Peptides TFF1 and TFF3 Synthesized in Human Conjunctival Goblet Cells", Invest Ophthalmol Vis Sci., 1999, Vol. 40, 2220-2224
AK	Allen et al, "Its Role in Gastroduodenal Mucosal Protection", J. Clin Gastroenterol, 1998; 10 (Suppl 1): S93-S98
AL	Ligumsky et al, "Sucralfate Protection Against Gastrointestinal Damage: Possible Role of Prostanoids", Israel J. Med Sci 1986, 22: 801-806
AM	Dignass et al, "Trefoil Peptides Promote Epithelial Migration through a Transforming Growth Factor $\beta$ -independent Pathway", J. Clin. Invest., 94, 376-383
AN	Tabor et al, "Surface Forces and Surface Interactions", 1977, J. Colloid Interface Sci. 58: 2-13
AO	Good, "Surface Free Energy of Solids and Liquids: Thermodynamics, Molecular Forces, and Structure", Journal of Colloid Interface Sci., 1977, 59:398

EXAMINER \_\_\_\_\_

DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.